4.02 USD
+0.09 (+2.29%)
Taking everything into account, SRTS scores 5 out of 10 in our fundamental rating. SRTS was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While SRTS has a great health rating, there are worries on its profitability. While showing a medium growth rate, SRTS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SRTS has reported negative net income.
In the past year SRTS had a positive cash flow from operations.
SRTS had positive earnings in 4 of the past 5 years.
SRTS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SRTS's Return On Assets of -5.16% is fine compared to the rest of the industry. SRTS outperforms 65.96% of its industry peers.
Looking at the Return On Equity, with a value of -5.87%, SRTS is in the better half of the industry, outperforming 69.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.16% | ||
| ROE | -5.87% | ||
| ROIC | N/A |
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRTS's Profit Margin has been stable in the last couple of years.
SRTS's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 47.95%, SRTS is in line with its industry, outperforming 42.55% of the companies in the same industry.
In the last couple of years the Gross Margin of SRTS has declined.
The Profit Margin and Operating Margin are not available for SRTS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.95% |
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
2. Health
2.1 Basic Checks
SRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
SRTS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SRTS remains at a similar level compared to 5 years ago.
There is no outstanding debt for SRTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SRTS has an Altman-Z score of 6.99. This indicates that SRTS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of SRTS (6.99) is better than 85.11% of its industry peers.
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.99 |
ROIC/WACCN/A
WACC8.7%
2.3 Liquidity
SRTS has a Current Ratio of 7.38. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SRTS (7.38) is better than 87.77% of its industry peers.
A Quick Ratio of 5.27 indicates that SRTS has no problem at all paying its short term obligations.
SRTS's Quick ratio of 5.27 is amongst the best of the industry. SRTS outperforms 84.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.38 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
The earnings per share for SRTS have decreased strongly by -133.33% in the last year.
The Earnings Per Share has been growing by 18.56% on average over the past years. This is quite good.
SRTS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.80%.
Measured over the past years, SRTS shows a quite strong growth in Revenue. The Revenue has been growing by 8.93% on average per year.
EPS 1Y (TTM)-133.33%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-185.71%
Revenue 1Y (TTM)-13.8%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%-22.12%
3.2 Future
Based on estimates for the next years, SRTS will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.64% on average per year.
Based on estimates for the next years, SRTS will show a quite strong growth in Revenue. The Revenue will grow by 14.67% on average per year.
EPS Next Y-184.15%
EPS Next 2Y-26.39%
EPS Next 3Y17.74%
EPS Next 5Y11.64%
Revenue Next Year-22.17%
Revenue Next 2Y7.08%
Revenue Next 3Y14.93%
Revenue Next 5Y14.67%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SRTS. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 18.55, SRTS is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRTS indicates a rather cheap valuation: SRTS is cheaper than 80.85% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.46, SRTS is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.55 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, SRTS is valued a bit cheaper than 78.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.5 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SRTS's earnings are expected to grow with 17.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.39%
EPS Next 3Y17.74%
5. Dividend
5.1 Amount
SRTS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SRTS (11/21/2025, 8:01:08 PM)
4.02
+0.09 (+2.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners29.15%
Inst Owner Change-14.95%
Ins Owners16.61%
Ins Owner Change0.12%
Market Cap66.09M
Revenue(TTM)35.61M
Net Income(TTM)-3.01M
Analysts82
Price Target7.48 (86.07%)
Short Float %4.31%
Short Ratio5.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-144.08%
Min EPS beat(2)-326.24%
Max EPS beat(2)38.08%
EPS beat(4)1
Avg EPS beat(4)-219.59%
Min EPS beat(4)-561.36%
Max EPS beat(4)38.08%
EPS beat(8)5
Avg EPS beat(8)85.83%
EPS beat(12)6
Avg EPS beat(12)12.6%
EPS beat(16)8
Avg EPS beat(16)15.03%
Revenue beat(2)1
Avg Revenue beat(2)-7.99%
Min Revenue beat(2)-22.89%
Max Revenue beat(2)6.91%
Revenue beat(4)3
Avg Revenue beat(4)3.8%
Min Revenue beat(4)-22.89%
Max Revenue beat(4)18.13%
Revenue beat(8)7
Avg Revenue beat(8)32.09%
Revenue beat(12)7
Avg Revenue beat(12)12.6%
Revenue beat(16)10
Avg Revenue beat(16)14.6%
PT rev (1m)-8.33%
PT rev (3m)-8.33%
EPS NQ rev (1m)-266.67%
EPS NQ rev (3m)-156.12%
EPS NY rev (1m)0%
EPS NY rev (3m)-166.13%
Revenue NQ rev (1m)-2%
Revenue NQ rev (3m)-25.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.55 | ||
| P/S | 1.86 | ||
| P/FCF | 30.5 | ||
| P/OCF | 34.64 | ||
| P/B | 1.29 | ||
| P/tB | 1.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.19
EYN/A
EPS(NY)0.22
Fwd EY5.39%
FCF(TTM)0.13
FCFY3.28%
OCF(TTM)0.12
OCFY2.89%
SpS2.17
BVpS3.11
TBVpS3.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.16% | ||
| ROE | -5.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.95% | ||
| FCFM | 6.09% |
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
F-Score4
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 115.63% | ||
| Cap/Sales | 0.73% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.38 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 6.99 |
F-Score4
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)82.92%
Cap/Depr(5y)64.01%
Cap/Sales(3y)0.65%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-133.33%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-185.71%
EPS Next Y-184.15%
EPS Next 2Y-26.39%
EPS Next 3Y17.74%
EPS Next 5Y11.64%
Revenue 1Y (TTM)-13.8%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%-22.12%
Revenue Next Year-22.17%
Revenue Next 2Y7.08%
Revenue Next 3Y14.93%
Revenue Next 5Y14.67%
EBIT growth 1Y-145.49%
EBIT growth 3Y25.22%
EBIT growth 5YN/A
EBIT Next Year-143.74%
EBIT Next 3Y-12.48%
EBIT Next 5Y-27.34%
FCF growth 1Y114.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y112.79%
OCF growth 3YN/A
OCF growth 5YN/A
SENSUS HEALTHCARE INC / SRTS FAQ
What is the ChartMill fundamental rating of SENSUS HEALTHCARE INC (SRTS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to SRTS.
Can you provide the valuation status for SENSUS HEALTHCARE INC?
ChartMill assigns a valuation rating of 3 / 10 to SENSUS HEALTHCARE INC (SRTS). This can be considered as Overvalued.
What is the profitability of SRTS stock?
SENSUS HEALTHCARE INC (SRTS) has a profitability rating of 3 / 10.
What is the expected EPS growth for SENSUS HEALTHCARE INC (SRTS) stock?
The Earnings per Share (EPS) of SENSUS HEALTHCARE INC (SRTS) is expected to decline by -184.15% in the next year.